Andrew Guggenhime - 30 Dec 2022 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
President and CFO
Signature
Andrew Guggenhime, by /s/ Ron A. Metzger, Attorney-in-Fact
Issuer symbol
PCVX
Transactions as of
30 Dec 2022
Net transactions value
+$126,747
Form type
4
Filing time
04 Jan 2023, 15:30:20 UTC
Previous filing
21 Sep 2022
Next filing
23 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $126,747 +23,691 +63% $5.35 61,229 30 Dec 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Award $0 +42,000 $0.000000 42,000 30 Dec 2022 Common Stock 42,000 $47.95 Direct F1
transaction PCVX Stock Option (right to buy) Options Exercise $0 -23,691 -5.2% $0.000000 430,827 30 Dec 2022 Common Stock 23,691 $5.35 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F2 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.